Journal Article Epublish 2 citations
PubMed: 40395345 DOI: 10.1002/smsc.202400521
Targeting Nanotherapeutics for Highly Efficient Diagnosis and Treatment of Systemic Lupus Erythematosus through Regulation of Immune Response.
Small Sci 5(5):2400521
Authors: Ting Liu, Zhiming Lin, Xi Zhang, Yu Yang, Guanning Huang, Yanzi Yu, Bin Xie, Lizhen He, Tianfeng Chen
Affiliations
- The Department of Chemistry Department of Neurology and Stroke Center of The First Affliated Hospital State Key Laboratory of Bioactive Molecules and Druggablily Assessment MOE Key Laboratory of Viral Pathogenesis and lnfection Prevention and Control Jinan University Guangzhou 510632 China.
- Division of Rheumatology Third Affiliated Hospital of Sun Yat-Sen University Guangzhou 510630 China.
Abstract
Systemic lupus erythematosus (SLE) is characterized by the production of pathogenic autoantibodies, particularly antidouble-stranded (ds) DNA antibodies, which contribute to multiorgan damage (lupus nephritis, LN). Hence, there is an urgent need to recognize and eliminate SLE-specific anti-ds DNA antibodies to enhance the SLE treatment. Herein, mesoporous silica (MSNs) loaded with SeC and surface-modified ctDNA are constructed to effectively specific bind and eliminate pathogenic anti-dsDNA antibodies for treatment SLE in 125 plasm and enabling swift LN diagnosis in 36 kidney tissue from SLE patients. As expected, the clearance ratio of anti-dsDNA antibodies by nanotherapeutics is significantly greater compared to other products commonly used in clinical therapies and exhibits biocompatibility and safety in patients. Moreover, MSNs-DNA can also help visualize the distribution of anti-dsDNA antibodies in the lesions of the kidney. Importantly, the combination strategy (MSNs-DNA@SeC) can effectively remove antibodies and reduce UP production by the regulation of B cells and T cells in female MRL/lpr SLE model mice to alleviate related symptoms. Collectively, the resultant data not only presents a straightforward method for the systematic design of nanomedicine targeting SLE to enhance the effects on diagnosis and treatment, but also elucidates the potential mechanisms involving anti-dsDNA antibodies in the pathogenesis and progression of SLE.
MeSH
Cells, Antibodies, Kidney, Lupus Erythematosus, Systemic, Immunity, Diagnosis, Therapeutics